Reviewed by Nabus Research · last reviewed 2026-07-12 · about our review process

▲ Human lifespan evidence: no lifespan RCT — a phase 2 human trial (frailty/inflammation) is ongoing with no efficacy results published

What it is

Class: Flavonoid senolytic / senotherapeutic

Also known as: 3,3',4',7-tetrahydroxyflavone

Relationship to senescence: A plant flavonoid identified as the most potent senolytic among a panel of flavonoids in preclinical screening; reduces senescence markers in multiple tissues via a hit-and-run mechanism.

Regulatory status

Sold as a dietary supplement; not an approved drug and not approved as a senolytic or for any longevity indication. Trial doses (e.g. 20 mg/kg/day for 2 days) far exceed typical supplement labelling and are used only under study protocols.

Mechanism

Reduces senescent-cell burden and SASP markers in aged/progeroid animal tissue; human trials target frailty and inflammation biomarkers. See /senolytics-vs-senomorphics.

Animal lifespan evidence

Animal lifespan evidence: yes

Late-life oral fisetin extended median and maximum lifespan in wild-type mice (Yousefzadeh et al., 2018). Single publication; not independently replicated in this dataset.

This is separate from human lifespan evidence, which is none for every intervention on this site. An animal lifespan result is not a human lifespan result.

Evidence — Mouse (wild-type, aged; progeroid models) verify: verified against primary source

Species / population	Aged wild-type mice and progeroid models.
Exposure, route, schedule	Intermittent/late-life oral fisetin.
Comparator / duration	Vehicle-treated age-matched controls.
Endpoint / numeric result	Reduced senescence markers across tissues; extended median and maximum lifespan when begun late in life (Yousefzadeh 2018).
What it did NOT establish	Mouse lifespan does not establish a human lifespan or healthspan effect.

Evidence — Human (phase 2, ongoing) verify: registry-verified; no results published yet

Species / population	Older adults with frailty/multimorbidity (AFFIRM / AFFIRM-LITE, older women and mixed cohorts).
Exposure, route, schedule	Oral fisetin 20 mg/kg/day for 2 days vs placebo (double-blind).
Comparator / duration	Placebo-controlled, randomized.
Endpoint / numeric result	Frailty (gait speed) and inflammatory markers — trial ongoing.
What it did NOT establish	No efficacy results are published; do not infer benefit from trial existence.

Negative or null findings

As of the search date, no peer-reviewed efficacy results from the human phase 2 fisetin trials had been published.

The form used in the trials

A product-fact block, not a recommendation. It records the form the trials used and what they administered. SeneSIQ does not rank products, name a best one, suggest a dose, or claim an effect.

Amount used in the trials	Oral fisetin 20 mg/kg/day for 2 days vs placebo (double-blind).
Trial population	Older adults with frailty/multimorbidity (AFFIRM / AFFIRM-LITE, older women and mixed cohorts).
Regulatory status	Sold as a dietary supplement; not an approved drug and not approved as a senolytic or for any longevity indication. Trial doses (e.g. 20 mg/kg/day for 2 days) far exceed typical supplement labelling and are used only under study protocols.

Find Fisetin on Amazon →

The search returns several variants. The trials used Fisetin, a plant flavonoid. The human trials used plain oral fisetin, not a branded formulation.

Links marked with an arrow are affiliate links: SeneSIQ may earn a commission if you buy through them, at no extra cost to you. This never affects what is published — see the affiliate disclosure.

Fisetin